Project Grant HT9425261E357
Award Date 8/15/26
Completion Date 8/14/28
Dollars Obligated $560K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
- Grant Award Summary The Defense Health Agency awarded The Wistar Institute of Anatomy and Biology a $442,557 Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective September 15, 2025, through September 14, 2028. The award funds research focused on immunotherapeutic targeting of SLC39A9 in CDKN2A-low melanoma, representing a translational research initiative designed to advance cancer immunotherapy approaches for military and public health benefit....
- The Defense Health Agency awarded The Wistar Institute of Anatomy and Biology $750,000 on July 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to develop novel biologics targeting Siglec-7/9 for activating and engaging natural killer cells and macrophages in the treatment of advanced breast cancer. The work is performed in Philadelphia, Pennsylvania, with a period of performance extending through June 30, 2029. The award supports basic and translational...
- <p>The Defense Health Agency awarded The Wistar Institute of Anatomy and Biology $1.05 million on November 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to investigate metabolic control of immune cold CCNE1-driven ovarian cancers. Performance occurs in Philadelphia, Pennsylvania, with work concluding October 31, 2029.</p>
- The Department of Defense's Defense Health Agency awarded a $1,194,425 Project Grant to The Wistar Institute of Anatomy and Biology to support a 3-year research project titled "DEVELOPING RATIONAL APPROACHES FOR ACRAL MELANOMA" under the Military Medical Research and Development program (CFDA 12.420). The grant will fund basic, translational, and clinical research aimed at developing new treatments and advancing scientific understanding of acral melanoma, a rare form of skin cancer. As...
- Federal Project Grant Summary The Defense Health Agency (DHA) awarded The Wistar Institute of Anatomy and Biology a $1.10M Project Grant under the Military Medical Research and Development program (CFDA 12.420) for research titled "Immunotherapeutic Targeting of SLC39A9 in CDKN2A-Low Melanoma." The three-year award, effective September 15, 2025 through September 14, 2028, supports hypothesis-driven biomedical research designed to advance cancer immunotherapy approaches for melanoma....
- The U.S. Defense Health Agency awarded a $999,006 Project Grant to The Wistar Institute of Anatomy and Biology in Philadelphia, PA under the Military Medical Research and Development program (CFDA 12.420). The grant, effective September 30, 2023 through September 29, 2026, will fund research on Epstein-Barr virus-driven B-cell inflammation and central nervous system trafficking in multiple sclerosis. The Wistar Institute has previously served as a subcontractor on federal grants, providing...
- The Defense Health Agency awarded the University of Pittsburgh $1,462,665 on July 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to investigate the intratumoral microbiome in acral melanoma. The three-year project runs through June 30, 2029, and is performed in Pittsburgh, Pennsylvania. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform health care for Service Members and the American...
- The Defense Health Agency awarded Yale University $1.05 million on July 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to conduct research on harnessing myeloid cell ontogeny to prevent melanoma brain metastasis. The award funds basic and applied biomedical research intended to transform health care for Service Members and the American public through innovative research and investigation of medical solutions for the battlefield. Performance will occur in New...
- The Defense Health Agency awarded The Washington University $140,000 on September 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to identify small molecules targeting the P14ARF pathway to treat CDKN2A-deficient malignant peripheral nerve sheath tumor. Work is performed in University City, Missouri, with a period of performance through August 31, 2028. The award is structured as a Project Grant, a common assistance type within the Defense Health Program's...
- The Defense Health Agency awarded The Washington University Office of Sponsored Research Services $140,000 on September 1, 2026, to conduct spatial profiling of myeloid cells in the tumor immune microenvironment of primary and metastatic medullary thyroid carcinomas under the Military Medical Research and Development program (CFDA 12.420). Work is performed in University City, Missouri, with an anticipated completion date of August 31, 2028. The project falls within the Defense Health Agency's...